Original and generic Tamsulosin: is there a difference?
https://doi.org/10.21518/2079-701X-2014-19-80-88
Abstract
Antagonists of α1-adrenergic receptors (α-blockers) are among the most effective drugs for the treatment of patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH; LUTS/BPH). Based on the results of treatment outcome analysis, the American Urological Association acknowledged these drugs as drugs of choice for the treatment of BPH [1].
About the Authors
SK Zyryanov
Pirogov Russian National Research Medical University, Russia’s Ministry of Health
Russian Federation
Russian Federation
YB Belousov
Pirogov Russian National Research Medical University, Russia’s Ministry of Health
Russian Federation
Russian Federation
А. AV Kamayev
National Agency for Clinical Pharmacology and Pharmacy, Moscow
Russian Federation
Russian Federation
GG Krivoborodov
Pirogov Russian National Research Medical University, Russia’s Ministry of Health
Russian Federation
Russian Federation
References
1. Roehrborn CG, Mc Connel J, Barry MJ et al. Guideline on the Management of Benign Prostatic Hypertrophy. AUA website: http://www.auanet.org/content/guidelines-and- quality-care/clinical-guidelines/main-reports/bph-management/preface_toc.pdf.
2. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on a1-adrenoceptor antagonists. BJUInt., 2005, 95 (Suppl. 4): 29-36.
3. van Dijk MM, de la Rosette JJMCH, Michel MC. Tamsulosin - modifi ed-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy, 2006, 3: 237-246.
4. McConell ID, Roeborn CG, Bautista OM et al. The long-term effect of doxazozine, finasteride, and combination therapy on the clinical progression of bening prostatic hyperplasia. N Engl. J. Med.,, 2003, 349: 2387-98.
5. Lepor H. Long-term efficacy and safety of terazosin in patients with bening prostatic hyperplasia. Terazosin Research Group. Urology, 1995, 45: 406-13.
6. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to bening prostatic hyperplasia. Int. J. Clin. Pract, 2008, 62 (10): 1547-1559.
7. www.grls.rosminzdrav.ru
8. Division of Drug Management and Policies. Summary of Counterfeit Drug Database as of April 1999 [unpublished manuscript]. Geneva, Switzerland: World Health Organization; 1999.
9. Пушкарь Д.Ю., Белоусов Ю.Б., Раснер П.И., Духанин А.С., Манешина О.А. Исследование степени уроселективности препарата Омник (тамсулозин) и его генерических аналогов. Consilium medicum, 2009, 7: 3-6.
Review
For citations:
Zyryanov S, Belousov Y, Kamayev A, Krivoborodov G. Original and generic Tamsulosin: is there a difference? Meditsinskiy sovet = Medical Council. 2014;(19):80-88. (In Russ.) https://doi.org/10.21518/2079-701X-2014-19-80-88
Views:
777
Email this article 